← Leaderboards
Tasneem Bawa-Khalfe
University Of Texas Hlth Sci Ctr Houston
$1,860,616
Attributed
$1,860,616
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $369.7K · FY2006–25$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,860,616 · 2
By mechanism
R01$1,761,392 · 1
F32$99,224 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Nami McCarty$4,379,218
- Edward T.h. Yeh$4,469,973
Others in their field
Top investigators on “Neoplasm Metastasis”
- Charles A Coltman · Southwest Oncology Group$110,022,912
- Timothy J Eberlein · Washington University$54,581,241
- Samuel A Wells · Duke University$31,864,469
- William George Nelson · Johns Hopkins University$31,104,956
- Zaver M Bhujwalla · Johns Hopkins University$30,433,864
- Leonidas C Platanias · University Of Illinois At Chicago$30,290,986
Research focus
Neoplasm MetastasisGrowthProteinsReportingAndrogensAndrogen ReceptorLaboratoriesPropertyUbiquitinTumor GrowthMalignant NeoplasmsEnzymesAndrogen AntagonistsBindingAr GeneAdvanced Breast CancerGenetic SignatureDesignChemosensitizationChromatinClinically RelevantClinical TrialsCancer ModelEffective Therapy
Grant awards (8)
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer$355,935
R01 · FY2025 · CA · contact PI
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer$338,138
R01 · FY2024 · CA · contact PI
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer$348,817
R01 · FY2023 · CA · contact PI
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer$348,817
R01 · FY2022 · CA · contact PI
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer$369,685
R01 · FY2021 · CA · contact PI
Role of SENP1 in Prostate Cancer Pathogenesis$35,952
F32 · FY2007 · CA · contact PI
Role of SENP1 in Prostate Cancer Pathogenesis$14,476
F32 · FY2007 · CA · contact PI
Role of SENP1 in Prostate Cancer Pathogenesis$48,796
F32 · FY2006 · CA · contact PI